RecruitingPhase 1Phase 2NCT05211986

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

An Open-label Dose Escalation Study to Assess the Safety and Tolerability of IMM01-STEM in Participants With Muscle Atrophy Related to Knee Osteoarthritis

Sponsor

Immunis, Inc.

Enrollment

28 participants

Start Date

Sep 13, 2022

Study Type

INTERVENTIONAL

Conditions

Muscle Atrophy

Summary

An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis

Eligibility

Min Age: 50 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IMM01-STEM for people with muscle atrophy. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 50 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIMM01-STEM

IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.

Locations(2)

Orthopaedic Specialty Institute

Irvine, California, United States

University of California, Irvine - Alpha Stem Cell Clinic

Orange, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05211986

Related Trials

Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )

NCT059199404 locations

A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure

NCT056274402 locations